Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VSV-IFNbetaTYRP1 |
Synonyms | |
Therapy Description |
VSV-IFNbetaTYRP1 is a oncolytic vesicular stomatitis virus engineered to express interferon-beta (IFNbeta) and TYRP1, which potentially induces activation of immune cells and enhances the immune response against tumor cells expressing TYRP1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VSV-IFNbetaTYRP1 | VSV-IFN-b/TYRP1|recombinant VSV-IFNbetaTYRP1 | VSV-IFNbetaTYRP1 is a oncolytic vesicular stomatitis virus engineered to express interferon-beta (IFNbeta) and TYRP1, which potentially induces activation of immune cells and enhances the immune response against tumor cells expressing TYRP1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03865212 | Phase I | VSV-IFNbetaTYRP1 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Active, not recruiting | USA | 0 |